PDCD1 and breast cancer: In the advanced trastuzumab-resistant HER2-positive BC (known as PANACEA) phase Ib/II study, the efficacy of anti-PD-1 pembrolizumab in combination with trastuzumab was evaluated in metastatic HER2+ BC patients.